Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

Assertio Announces the Appointment of Brendan P. O’Grady as New CEO Assertio appoints Brendan P. O'Grady as CEO

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Assertio Holdings, Inc....

ASSERTIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed...

ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner...